Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
J Contemp Brachytherapy ; 7(1): 10-6, 2015 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-25829931

RESUMO

PURPOSE: High-dose-rate (HDR) brachytherapy has been accepted as an effective and safe method to treat prostate cancer. The aim of this study was to describe acute toxicity following HDR brachytherapy to the prostate, and to examine the association between dosimetric parameters and urinary toxicity in low-risk prostate cancer patients. MATERIAL AND METHODS: Patients with low-risk prostate cancer were given HDR brachytherapy as monotherapy in two 12.5 Gy fractions. Planning objectives for the planning target volume (PTV) were V100% ≥ 90% and V150% ≤ 35%. Planning objectives for organs at risk were V75% ≤ 1 cc for the bladder, rectum and perineum, and V125% ≤ 1 cc for the urethra. Toxicity was assessed three months after treatment using the Common Terminology Criteria for Adverse Events. RESULTS: Seventy-three patients were included in the analysis. Thirty-three patients (45%) reported having any type of toxicity in the three months following HDR brachytherapy. Most toxicity cases (26%) were grade 1 urinary toxicity. Mean coverage index was 0.89 and mean V100 was 88.85. Doses administered to the urethra were associated with urinary toxicity. Patients who received more than 111.3% of the prescribed dose in 1 cc of the urethra were four times more likely to have urinary toxicity compared to patients receiving less than 111.3% (OR = 4.71, 95% CI: 1.43-15.6; p = 0.011). CONCLUSIONS: High-dose-rate brachytherapy administered as monotherapy for prostate cancer proved to be a safe alternative treatment for patients with low-risk prostate cancer. Urinary toxicity was associated with the dose administered to 1 cc and 0.1 cc of the urethra and was remarkably inferior to the reported toxicity in similar studies.

2.
Rev. colomb. cancerol ; 19(2): 119-122, abr.-jun. 2015. ilus, tab
Artigo em Espanhol | LILACS | ID: lil-765561

RESUMO

Las imágenes de simulación obtenidas mediante TAC son actualmente el estándar para uso en los sistemas de planificación de haces externos empleados en los tratamientos de radioterapia. Sin embargo, una de las limitaciones es su bajo contraste y poca especificidad para la identificación y caracterización de lesiones tumorales y algunas estructuras a nivel de sistema nervioso central. Los nuevos algoritmos implementados en los sistemas de planificación de radioterapia permiten realizar la fusión de imágenes de RM con TAC de simulación, definir y proteger estructuras como el hipocampo, buscando administrar dosis bajas en esta zona, lograr mayores dosis a los volúmenes tumorales y disminuir los efectos secundarios derivados de tratamientos holoencefálicos con radioterapia. En este artículo se presentan las imágenes correspondientes a esta técnica de tratamiento.


CT simulation images are the current standard in external beam radiotherapy planning systems. However, the limitations of images obtained from CT scanning include their low contrast and low specificity in the identification and characterization of tumor lesions and some central nervous system structures. The new algorithms implemented in radiotherapy planning systems allow image fusion to be performed using MRI images and CT simulation images. It also allows structures like the hippocampus to be defined and protected, by administering lower Radiosurgery; doses to this area and higher doses to the tumor volume, thus decreasing side effects arising from whole brain radiotherapy treatment. Images corresponding to this treatment technique are presented in this article.


Assuntos
Humanos , Imageamento por Ressonância Magnética , Tomografia Computadorizada de Emissão , Radiocirurgia , Cérebro , Terapêutica , Hipocampo , Metástase Neoplásica
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA